Why Fastenal Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Shares of Fastenal Company (NASDAQ:FAST) fell sharply during Thursday's session following worse-than-expected first-quarter financial results. Fastenal reported first-quarter FY24 sales growth of 1.9
SciSparc To Acquire AutoMax, A Strategic Leap Towards Industry Diversification
Specialty clinical-stage pharmaceutical company SciSparc Ltd. (NASDAQ:SPRC) has entered into a merger agreement with AutoMax Motors Ltd., a vehicle importer company in Israel. Deal terms not disclosed.
SciSparc: AutoMax's Outstanding Shares to Be Converted Into Right to Receive Ordinary Shares of SciSparc >SPRC
SciSparc: AutoMax's Outstanding Shares to Be Converted Into Right to Receive Ordinary Shares of SciSparc >SPRC
SciSparc Shareholders to Hold About 50.01% of Share Capital of the Post-Closing Combined Company >SPRC
SciSparc Shareholders to Hold About 50.01% of Share Capital of the Post-Closing Combined Company >SPRC
SciSparc To Acquire AutoMax >SPRC
SciSparc To Acquire AutoMax >SPRC
Why Rallybio Shares Are Trading Higher By Around 78%; Here Are 20 Stocks Moving Premarket
Shares of Rallybio Corporation (NASDAQ:RLYB) rose sharply in today's pre-market trading after the company announced a collaboration with Johnson & Johnson to advance therapeutics for pregnant individ
SciSparc Granted Canadian Patent #2984088 Titled "COMBINATIONS OF CANNABINOIDS AND N-ACYLETHANOLAMINES (FOR TREATMENT OF CONDITIONS SUCH AS MOVEMENT DISORDERS, BODY-WEIGHT GAIN, CONFUSION, DISORIENTATION, ANXIETY, AND PREVENTION OF PAIN)"
SciSparc Granted Canadian Patent #2984088 Titled "COMBINATIONS OF CANNABINOIDS AND N-ACYLETHANOLAMINES (FOR TREATMENT OF CONDITIONS SUCH AS MOVEMENT DISORDERS, BODY-WEIGHT GAIN, CONFUSION, DISORIENTAT
SciSparc- Clearmind Collaboration Evolves With New International Patent Application for Preventing and Treating Depression
TEL AVIV, Israel, March 27, 2024 (GLOBE NEWSWIRE) -- SciSparc Ltd. (NASDAQ:SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to
SciSparc Announces MitoCareX Unveils Groundbreaking Discovery Of Small Molecule Structure In Anti-Cancer Research
MitoCareX Bio dedicates efforts to creating a predictive AI model to predict small molecules more efficientlyTEL AVIV, Israel, March 21, 2024 (GLOBE NEWSWIRE) -- SciSparc Ltd. (NASDAQ:SPRC) ("Company"
TLRY, ACB and CGC Are Among Pre Market Gainers
SciSparc Granted Another Patent, Strengthening Its Core Technology in Canada
TEL AVIV, Israel, March 18, 2024 (GLOBE NEWSWIRE) -- SciSparc Ltd. (NASDAQ:SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders
SciSparc Achieves Major Milestone With First Patient Dosed in Autism Spectrum Disorder Clinical Trial
First patient has been dosed in the randomized, controlled, double blind clinical trial for Autism Spectrum Disorder in pediatric patients
Podcast: Clearmind's Non-Hallucinogenic Psychoactive Molecule Could Become A Solution For Addictive Behaviors
Welcome to a new episode of our Benzinga Psychedelics Podcast. We are joined herein by executives of Clearmind Medicine (NASDAQ:CMND), a biotech company developing a proprietary, psychoactive yet non-
SciSparc: MitoCareX Reveals Promising Results With Discovery of Novel Anti-Cancer Small Molecule Structure
Autism CBD Trial Enrolls Children: This Israeli Co. Is Making Headway In New Treatments
SciSparc Ltd. (NASDAQ:SPRC) announced on Friday that it has enrolled the first patient in the company's clinical trial assessing the efficacy and safety of its cannabidiol (CBD) – based drug for the t
Top Premarket Gainers
Ainos (AIMD) shares surged more than 149%, reversing Thursday's slide. CERo Therapeutics (CERO) shares rose 55%, extending Thursday's rally. Gulf Island Fabrication (GIFI) shares advanced 27% after th
SciSparc Announces Enrollment of First Patient for Its Clinical Trial for Children With Autism Spectrum Disorder
TEL AVIV, Israel, March 08, 2024 (GLOBE NEWSWIRE) -- SciSparc Ltd. (NASDAQ:SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to
Mind Medicine Sends Psychedelic Stocks Higher After FDA Status for LSD Formulation
SciSparc Granted Patent for Core Technology in Multiple Jurisdictions in Europe
The Company's most recent patent further solidifies its position, complementing existing grants in the U.S., Japan, Australia and other key jurisdictions TEL AVIV, Israel, March 07, 2024 (GLOBE NEWSWIRE) --
SciSparc Issued Canadian Patent for Opioids Reduction Use in Pain Management Technology
TEL AVIV, Israel, March 06, 2024 (GLOBE NEWSWIRE) -- SciSparc Ltd. (NASDAQ:SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to
No Data